GPR35 antagonist CID-2745687 attenuates anchorage-independent cell growth by inhibiting YAP/TAZ activity in colorectal cancer cells

FierceBiotechWhen Spray Drying Falls Short: A Faster Path Forward

FierceBiotechNovo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win

FierceBiotechRoche boosts diagnostics offerings with $595M Saga buyout

FierceBiotechLilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B

FierceBiotechBiogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody

ModernaWhat's Pushing Moderna Stock Higher Today? - Benzinga

Novo NordiskNovo Nordisk to seek oral sickle cell therapy approval after Phase III victory - Yahoo

AbbottDiane Abbott criticises Keir Starmer over Peter Mandelson vetting process - Sky News

Intuitive SurgicalIntuitive Surgical Q1 2026 Earnings Preview (ISRG:NASDAQ) - Seeking Alpha

Thermo FisherThermo Fisher: Great Business Still Trading At A Risky Price Before Earnings (NYSE:TMO) - Seeking Alpha

Thermo FisherHere's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today - Benzinga

BioWorldBiggest gainers and losers for April 13-17, 2026